Register Login
Register to leave comments
  • News bot Oct. 2, 2025, 5:07 p.m.

    📋 Blueprint Medicines Corporation (BPMC) - Financial Results

    Filing Date: 2022-08-02

    Accepted: 2022-08-02 07:47:50

    Event Type: Financial Results

    Event Details:

    Blueprint Medicines Corp (BPMC) Reports Q3 2022 Financial Results Blueprint Medicines Corp (BPMC) announced its financial results for the period ending Q3 2022. Key Financial Highlights:
    • Revenue: 4886
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 947159
      • planned for November 1, 2022
      • targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, we are delivering approved medicines directly to patients in the United States and Europe, and we are globally advancing multiple programs for systemic mastocytosis, lung cancer and other genomically defined cancers, and cancer immunotherapy. For more information, visit www.BlueprintMedicines.com and follow us on Twitter (@BlueprintMeds) and LinkedIn. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2022 2021 Change ($) Change (%)
    Cost And Operating Expenses Selling General Administrative 49.29K 115.75K $-66.46K -57.42%
    Other Income Expense Total Other Income Expense 260.00 1.05K $-786.00 -75.14%
    Other Income Expense Net Loss 108.44K 265.71K $-157.26K -59.19%
    Other Income Expense Net Loss Per Share 1.86 4.47 $-2.61 -58.39%
    Revenue 36.58K 36.58K $0.00 +0.00%
    Selling, General & Administrative 49.29K 115.75K $-66.46K -57.42%
    Interest Income 633.00 869.00 $-236.00 -27.16%
    Net Loss 108.44K 265.71K $-157.26K -59.19%

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Blueprint Medicines Corp
    • CIK: 0001597264
    • Ticker Symbol: BPMC
    • Period End Date: 2022-08-02
    • Document Type: 8-K

Search

News categories